**Supplementary Table.** **Primary efficacy analysis: mean change from baseline in BCVA**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **DEX implant** | **Ranibizumab** | **p valuea** |
| ***Overall study population (n = 307)*** |
| Mean change from baseline in BCVA at month 12 No. of eyes Least-squares mean (± SE), ETDRS letters Difference DEX-RAN (95% CI), ETDRS letters | 1547.4 (1.0)-10.1 (-12.9, -7.2) | 15317.4 (1.0) | 0.0006 |
| Average change in BCVA - baseline to month 3 No. of eyes Least-squares mean (±SE), ETDRS letters Difference DEX-RAN (95% CI), ETDRS letters | 15410.0 (0.6)-2.8 (-4.5, -1.1) | 15312.8 (0.6) | 0.0096 |
| Average change in BCVA - baseline to month 12 No. of eyes Least-squares mean (± SE), ETDRS letters Difference DEX-RAN (95% CI), ETDRS letters | 1549.3 (0.7)-6.3 (-8.3, -4.2) | 15315.5 (0.7) | 0.2190 |
| ***Pseudophakic eyes (*n *= 53)*** |  |  |  |
| Mean change from baseline in BCVA at month 12 No. of eyes Least-squares mean (± SE), ETDRS letters Difference DEX-RAN (95% CI), ETDRS letters | 264.4 (3.1)-7.4 (-16.0, +1.3) | 2711.7 (3.0) | 0.5829 |

BCVA = best-corrected visual acuity; CI = confidence interval; ETDRS = Early Treatment Diabetic Retinopathy Score; SE = standard error of the mean.

a ANCOVA model, p value for treatment.effect